

Don Diamond

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8894640/publications.pdf>

Version: 2024-02-01

186
papers

6,827
citations

41323

49
h-index

82499

72
g-index

193
all docs

193
docs citations

193
times ranked

7017
citing authors

#	ARTICLE	IF	CITATIONS
1	Large-scale manufacturing and characterization of CMV-CD19CAR T cells. , 2022, 10, e003461.		9
2	Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates. <i>Npj Vaccines</i> , 2022, 7, 7.	2.9	35
3	Putative Protective Role of Sars-Cov-2-Specific T Cells in an HCT Patient Transplanted during Active COVID19 Infection. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S359-S360.	0.6	0
4	CMV Triplex Vaccine to Enhance Adaptive NK and T-cell Reconstitution After Autologous Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 343.e1-343.e4.	0.6	2
5	Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial. <i>Lancet Microbe</i> , The, 2022, 3, e252-e264.	3.4	29
6	COH04S1 and beta sequence-modified vaccine protect hamsters from SARS-CoV-2 variants. <i>IScience</i> , 2022, 25, 104457.	1.9	8
7	Vaccine-induced spike- and nucleocapsid-specific cellular responses maintain potent cross-reactivity to SARS-CoV-2 Delta and Omicron variants. <i>IScience</i> , 2022, 25, 104745.	1.9	11
8	Inhibition of <i>de novo</i> pyrimidine synthesis augments Gemcitabine induced growth inhibition in an immunocompetent model of pancreatic cancer. <i>International Journal of Biological Sciences</i> , 2021, 17, 2240-2251.	2.6	8
9	Development of CMV-CD19 bi-specific CAR T cells with post-infusion in vivo boost using an anti-CMV vaccine. <i>International Journal of Hematology</i> , 2021, 114, 544-553.	0.7	6
10	A Phase II Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy of Cmvpepvax for Preventing CMV Reactivation/Disease after Matched Related/Unrelated Donor Hematopoietic Cell Transplant. <i>Blood</i> , 2021, 138, 2887-2887.	0.6	0
11	Protection against Congenital CMV Infection Conferred by MVA-Vectored Subunit Vaccines Extends to a Second Pregnancy after Maternal Challenge with a Heterologous, Novel Strain Variant. <i>Viruses</i> , 2021, 13, 2551.	1.5	0
12	Salmonella-mediated therapy targeting indoleamine 2, 3-dioxygenase 1 (IDO) activates innate immunity and mitigates colorectal cancer growth. <i>Cancer Gene Therapy</i> , 2020, 27, 235-245.	2.2	42
13	Cytomegalovirus-vectored vaccines for HIV and other pathogens. <i>Aids</i> , 2020, 34, 335-349.	1.0	10
14	Inhibition of Autophagy Amplifies Baicalein-Induced Apoptosis in Human Colorectal Cancer. <i>Molecular Therapy - Oncolytics</i> , 2020, 19, 1-7.	2.0	32
15	Personal Protective Equipment and COVID-19. <i>Annals of Surgery</i> , 2020, 272, e132-e138.	2.1	46
16	Poxvirus Vectored Cytomegalovirus Vaccine to Prevent Cytomegalovirus Viremia in Transplant Recipients. <i>Annals of Internal Medicine</i> , 2020, 172, 306.	2.0	45
17	Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform. <i>Nature Communications</i> , 2020, 11, 6121.	5.8	71
18	Exciting Times for Cytomegalovirus (CMV) Vaccine Development: Navigating the Pathways toward the Goal of Protecting Infants against Congenital CMV Infection. <i>Vaccines</i> , 2020, 8, 526.	2.1	11

#	ARTICLE	IF	CITATIONS
19	The Status of Vaccine Development Against the Human Cytomegalovirus. <i>Journal of Infectious Diseases</i> , 2020, 221, S113-S122.	1.9	73
20	5-Azacytidine Potentiates Anti-tumor Immunity in a Model of Pancreatic Ductal Adenocarcinoma. <i>Frontiers in Immunology</i> , 2020, 11, 538.	2.2	15
21	Modeling Human Cytomegalovirus-Induced Microcephaly in Human iPSC-Derived Brain Organoids. <i>Cell Reports Medicine</i> , 2020, 1, 100002.	3.3	67
22	Chimeric Antigen Receptors Targeting Human Cytomegalovirus. <i>Journal of Infectious Diseases</i> , 2020, 222, 853-862.	1.9	10
23	Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers. <i>Clinical and Translational Oncology</i> , 2019, 21, 363-372.	1.2	57
24	Desmoplasia and oncogene driven acinar-to-ductal metaplasia are concurrent events during acinar cell-derived pancreatic cancer initiation in young adult mice. <i>PLoS ONE</i> , 2019, 14, e0221810.	1.1	18
25	Rapid Acquisition of Cytomegalovirus-Specific T Cells with a Differentiated Phenotype, in Non-Viremic Hematopoietic Stem Transplant Recipients Vaccinated with Cmvpepvax. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S71-S72.	2.0	0
26	MVA-Vectored Pentameric Complex (PC) and gB Vaccines Improve Pregnancy Outcome after Guinea Pig CMV Challenge, but Only gB Vaccine Reduces Vertical Transmission. <i>Vaccines</i> , 2019, 7, 182.	2.1	11
27	Rapid Acquisition of Cytomegalovirus-Specific T Cells with a Differentiated Phenotype, in Nonviremic Hematopoietic Stem Transplant Recipients Vaccinated with CMVPepVax. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 771-784.	2.0	12
28	Adaptive NK cell reconstitution is associated with better clinical outcomes. <i>JCI Insight</i> , 2019, 4, .	2.3	59
29	Large-Scale Manufacturing of CMV-CD19CAR T Cells and Characterization of Their Biologic and Immunologic Properties. <i>Blood</i> , 2019, 134, 3247-3247.	0.6	1
30	p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy. <i>Clinical Cancer Research</i> , 2018, 24, 1315-1325.	3.2	47
31	Exploiting 2A peptides to elicit potent neutralizing antibodies by a multi-subunit herpesvirus glycoprotein complex. <i>Journal of Virological Methods</i> , 2018, 251, 30-37.	1.0	14
32	A fifty-year odyssey: prospects for a cytomegalovirus vaccine in transplant and congenital infection. <i>Expert Review of Vaccines</i> , 2018, 17, 889-911.	2.0	42
33	Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Responses against Human Cytomegalovirus in Mice. <i>Journal of Virology</i> , 2018, 92, .	1.5	31
34	A phase 1 study of p53MVA vaccine in combination with pembrolizumab.. <i>Journal of Clinical Oncology</i> , 2018, 36, 206-206.	0.8	11
35	Incidence and Risk Factors of CMV Reactivation after Haploidentical Hematopoietic Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide - Possible Role of Donor KIR Genotypes. <i>Blood</i> , 2018, 132, 3416-3416.	0.6	1
36	Identification of a Continuous Neutralizing Epitope within UL128 of Human Cytomegalovirus. <i>Journal of Virology</i> , 2017, 91, .	1.5	17

#	ARTICLE	IF	CITATIONS
37	MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults. <i>Blood</i> , 2017, 129, 114-125.	0.6	69
38	TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs. <i>Journal of Leukocyte Biology</i> , 2017, 102, 423-436.	1.5	47
39	The pancreatic cancer microenvironment: A true double agent. <i>Journal of Surgical Oncology</i> , 2017, 116, 7-15.	0.8	57
40	Plasmablast Response to Primary Rhesus Cytomegalovirus (CMV) Infection in a Monkey Model of Congenital CMV Transmission. <i>Vaccine Journal</i> , 2017, 24, .	3.2	15
41	Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab. <i>Oncolmmunology</i> , 2017, 6, e1363138.	2.1	20
42	Salmonella-Mediated Therapy Targeting Indoleamine 2, 3-Dioxygenase (IDO) Mitigates Colorectal Cancer Growth in an Immunocompetent. <i>Journal of the American College of Surgeons</i> , 2017, 225, S45-S46.	0.2	0
43	Neutralization of Human Cytomegalovirus Entry into Fibroblasts and Epithelial Cells. <i>Vaccines</i> , 2017, 5, 39.	2.1	22
44	Preexisting antibodies can protect against congenital cytomegalovirus infection in monkeys. <i>JCI Insight</i> , 2017, 2, .	2.3	63
45	Comparison of homologous and heterologous prime-boost vaccine approaches using Modified Vaccinia Ankara and soluble protein to induce neutralizing antibodies by the human cytomegalovirus pentamer complex in mice. <i>PLoS ONE</i> , 2017, 12, e0183377.	1.1	10
46	Developing Effective Salmonella-based Approaches to Treat Pancreatic Cancer. <i>Pancreatic Disorders & Therapy</i> , 2016, 06, 1-2.	0.3	2
47	Plasma IL-10 Levels to Guide Antiviral Prophylaxis Prevention of Late-Onset Cytomegalovirus Disease, in High Risk Solid Kidney and Liver Transplant Recipients. <i>Transplantation</i> , 2016, 100, 210-216.	0.5	10
48	Evaluation of innate and adaptive immunity contributing to the antitumor effects of PD1 blockade in an orthotopic murine model of pancreatic cancer. <i>Oncolmmunology</i> , 2016, 5, e1160184.	2.1	13
49	Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial. <i>Lancet Haematology</i> , 2016, 3, e87-e98.	2.2	67
50	CD56dimCD57+NKG2C+ NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT. <i>Leukemia</i> , 2016, 30, 456-463.	3.3	188
51	The susceptibility of primary cultured rhesus macaque kidney epithelial cells to rhesus cytomegalovirus strains. <i>Journal of General Virology</i> , 2016, 97, 1426-1438.	1.3	21
52	A phase I study of a p53MVA vaccine in combination with gemcitabine (GEM) in recurrent ovarian cancer (OC).. <i>Journal of Clinical Oncology</i> , 2016, 34, e17040-e17040.	0.8	0
53	Adaptive Natural Killer Cell and Killer Cell Immunoglobulin-Like Receptor-Expressing T Cell Responses are Induced by Cytomegalovirus and Are Associated with Protection against Cytomegalovirus Reactivation after Allogeneic Donor Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> . 2015, 21, 1653-1662.	2.0	50
54	Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors. <i>Cancer Immunology Research</i> , 2015, 3, 1096-1107.	1.6	58

#	ARTICLE	IF	CITATIONS
55	Reduced Frequencies of Polyfunctional CMV-Specific T Cell Responses in Infants with Congenital CMV Infection. <i>Journal of Clinical Immunology</i> , 2015, 35, 289-301.	2.0	26
56	CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells. <i>Clinical Cancer Research</i> , 2015, 21, 2993-3002.	3.2	52
57	Vaccine-Derived Neutralizing Antibodies to the Human Cytomegalovirus gH/gL Pentamer Potently Block Primary Cytotrophoblast Infection. <i>Journal of Virology</i> , 2015, 89, 11884-11898.	1.5	79
58	Maternal CD4 ⁺ T cells protect against severe congenital cytomegalovirus disease in a novel nonhuman primate model of placental cytomegalovirus transmission. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 13645-13650.	3.3	90
59	Comparison of monovalent glycoprotein B with bivalent gB/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: Inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection against pup mortality. <i>Vaccine</i> , 2015, 33, 4013-4018.	1.7	29
60	Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2015, 50, 26-33.	1.3	25
61	Safety, Maximum Tolerated Dose and Immunogenicity of CMV-MVA-Triplex in Healthy Volunteers with or without Prior Immunity to CMV and Vaccinia. <i>Blood</i> , 2015, 126, 3108-3108.	0.6	1
62	Human Cytomegalovirus Vaccine Based on the Envelope gH/gL Pentamer Complex. <i>PLoS Pathogens</i> , 2014, 10, e1004524.	2.1	106
63	Overcoming immunosuppression to enhance a p53MVA vaccine. <i>Oncotarget</i> , 2014, 3, e958949.	2.1	10
64	Ex vivo detection of CD8 T cells specific for H-Y minor histocompatibility antigens in allogeneic hematopoietic stem cell transplant recipients. <i>Transplant Immunology</i> , 2014, 30, 128-135.	0.6	4
65	p53MVA Therapy in Patients with Refractory Gastrointestinal Malignancies Elevates p53-Specific CD8+ T-cell Responses. <i>Clinical Cancer Research</i> , 2014, 20, 4459-4470.	3.2	32
66	Effective Cancer Vaccine Platform Based on Attenuated <i>Salmonella</i> and a Type III Secretion System. <i>Cancer Research</i> , 2014, 74, 6260-6270.	0.4	60
67	Development of a novel, guinea pig-specific IFN- γ ELISPOT assay and characterization of guinea pig cytomegalovirus GP83-specific cellular immune responses following immunization with a modified vaccinia virus Ankara (MVA)-vectored GP83 vaccine. <i>Vaccine</i> , 2014, 32, 3963-3970.	1.7	20
68	CMV Reactivation is Associated with Reduced Relapse Risk, Better Disease-Free Survival and Expansion of Adaptive NK Cells after Reduced Intensity Hematopoietic Cell Transplantation. <i>Blood</i> , 2014, 124, 668-668.	0.6	2
69	Clonal Expansion of Adaptive NK Cells and NKG2C+CD57+ KIR-Expressing T Cells from Sibling, but Not Umbilical Cord Blood, Grafts Is Induced By Recipient Latent CMV and Is Associated with Protection Against CMV Reactivation. <i>Blood</i> , 2014, 124, 181-181.	0.6	0
70	Randomized Trial of a Novel CMV Vaccine (CMVPepVax) after Allogeneic HCT: Elevated CMV-Specific Immune Response, Reduction in Chronic GvHD and CMV Reactivation Only in Vaccine Arm Patients. <i>Blood</i> , 2014, 124, 183-183.	0.6	0
71	TLR9 Signaling in the Tumor Microenvironment Initiates Cancer Recurrence after Radiotherapy. <i>Cancer Research</i> , 2013, 73, 7211-7221.	0.4	71
72	Detection and preliminary characterization of CD8+ T lymphocytes specific for Wilms' tumor antigen in patients with non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 2490-2499.	0.6	4

#	ARTICLE	IF	CITATIONS
73	A road less traveled paved by IDO silencing. <i>Oncolmmunology</i> , 2013, 2, e23322.	2.1	13
74	DNA vaccine prime followed by boost with live attenuated virus significantly improves antigen-specific T cell responses against human cytomegalovirus. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 2120-2132.	1.4	13
75	Tumor Growth Control with IDO-Silencing Salmonella. <i>Cancer Research</i> , 2013, 73, 4592-4593.	0.4	2
76	La Rosa C et al (J Infect Dis 2012; 205:1294-304). <i>Journal of Infectious Diseases</i> , 2013, 208, 1038-1038.	1.9	0
77	A Vaccine Based on the Rhesus Cytomegalovirus UL128 Complex Induces Broadly Neutralizing Antibodies in Rhesus Macaques. <i>Journal of Virology</i> , 2013, 87, 1322-1332.	1.5	81
78	A phase I study of an MVA vaccine targeting p53 in cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3089-3089.	0.8	2
79	Quantitative Monitoring Of Wilms's Tumor 1 Expression In Predicting Relapse After Allogeneic Hematopoietic Stem Cell Transplantation In Patients With Acute Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 2013, 122, 2075-2075.	0.6	0
80	Survivin the battle against immunosuppression. <i>Oncolmmunology</i> , 2012, 1, 240-241.	2.1	4
81	The immune response to human CMV. <i>Future Virology</i> , 2012, 7, 279-293.	0.9	135
82	Patterns of Acute Rhesus Cytomegalovirus (RhCMV) Infection Predict Long-Term RhCMV Infection. <i>Journal of Virology</i> , 2012, 86, 6354-6357.	1.5	19
83	Clinical Evaluation of Safety and Immunogenicity of PADRE-Cytomegalovirus (CMV) and Tetanus-CMV Fusion Peptide Vaccines With or Without PF03512676 Adjuvant. <i>Journal of Infectious Diseases</i> , 2012, 205, 1294-1304.	1.9	86
84	Systemic Delivery of Salmonella typhimurium Transformed with IDO shRNA Enhances Intratumoral Vector Colonization and Suppresses Tumor Growth. <i>Cancer Research</i> , 2012, 72, 6447-6456.	0.4	84
85	Intracerebral CpG Immunotherapy with Carbon Nanotubes Abrogates Growth of Subcutaneous Melanomas in Mice. <i>Clinical Cancer Research</i> , 2012, 18, 5628-5638.	3.2	52
86	Enhanced Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV Specific Central Memory T Cells by CMV Vaccine.. <i>Blood</i> , 2012, 120, 3014-3014.	0.6	0
87	Recombinant Modified Vaccinia Virus Ankara (MVA) Expressing Wild-Type Human p53 Induces Specific Antitumor CTL Expansion. <i>Cancer Investigation</i> , 2011, 29, 501-510.	0.6	12
88	CD154 Expression Is Associated with Neutralizing Antibody Titer Levels Postinfluenza Vaccination in Stem Cell Transplant Patients and Healthy Adults. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 524-533.	2.0	5
89	Characterization of immunologic properties of a second HLA-A2 epitope from a granule protease in CML patients and HLA-A2 transgenic mice. <i>Blood</i> , 2011, 118, 2159-2169.	0.6	14
90	Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipients. <i>Transplant International</i> , 2011, 24, 920-931.	0.8	22

#	ARTICLE	IF	CITATIONS
91	Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 99-109.	2.0	38
92	Enhancement of Cancer Vaccine Therapy by Systemic Delivery of a Tumor-Targeting Salmonella-Based STAT3 shRNA Suppresses the Growth of Established Melanoma Tumors. <i>Cancer Research</i> , 2011, 71, 4183-4191.	0.4	79
93	Open Reading Frames Carried on UL2 Are Implicated in Shedding and Horizontal Transmission of Rhesus Cytomegalovirus in Rhesus Monkeys. <i>Journal of Virology</i> , 2011, 85, 5105-5114.	1.5	51
94	Vaccine-Induced Control of Viral Shedding following Rhesus Cytomegalovirus Challenge in Rhesus Macaques. <i>Journal of Virology</i> , 2011, 85, 2878-2890.	1.5	47
95	Carbon Nanotubes Enhance CpG Uptake and Potentiate Antiglioma Immunity. <i>Clinical Cancer Research</i> , 2011, 17, 771-782.	3.2	147
96	Effect of gemcitabine on specific antitumor responses of modified vaccinia Ankara (MVA) expressing survivin in a murine pancreatic carcinoma model. <i>Journal of Clinical Oncology</i> , 2011, 29, 256-256.	0.8	0
97	Suppressing Immunosuppressive Pathways by RNA Interference Synergizes with Tumor Antigen Vaccines Causing Long-Term Regression of Established Subcutaneous Lymphomas. <i>Blood</i> , 2011, 118, 106-106.	0.6	0
98	Detection and Characterization of Antigen-Driven CD8+ T Lymphocytes Specific for Wilms' Tumor Antigen in Patients with Non-Hodgkin Lymphoma. <i>Blood</i> , 2011, 118, 953-953.	0.6	0
99	Heterologous Prime/Boost Immunization With p53-based Vaccines Combined With Toll-like Receptor Stimulation Enhances Tumor Regression. <i>Journal of Immunotherapy</i> , 2010, 33, 609-617.	1.2	28
100	Intergenic region 3 of modified vaccinia ankara is a functional site for insert gene expression and allows for potent antigen-specific immune responses. <i>Virology</i> , 2010, 403, 155-162.	1.1	17
101	Programmed death-1 receptor and interleukin-10 in liver transplant recipients at high risk for late cytomegalovirus disease. <i>Transplant Infectious Disease</i> , 2010, 12, 363-370.	0.7	26
102	Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines. <i>Vaccine</i> , 2010, 28, 1547-1557.	1.7	42
103	Predictors of reported influenza vaccination in HIV-infected women in the United States, 2006-2007 and 2007-2008 seasons. <i>Preventive Medicine</i> , 2010, 50, 223-229.	1.6	14
104	Mamu-A1/Kb transgenic and MHC Class I knockout mice as a tool for HIV vaccine development. <i>Virology</i> , 2009, 387, 16-28.	1.1	2
105	The Effect of Single and Combined Activating Killer Immunoglobulin-like Receptor Genotypes on Cytomegalovirus Infection and Immunity after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 315-325.	2.0	82
106	Increased Programmed Death-1 Molecule Expression in Cytomegalovirus Disease and Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 872-880.	2.0	37
107	Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients. <i>Blood</i> , 2009, 113, 6465-6476.	0.6	140
108	Evaluation of recombinant modified vaccinia Ankara virus-based rhesus cytomegalovirus vaccines in rhesus macaques. <i>Medical Microbiology and Immunology</i> , 2008, 197, 117-123.	2.6	37

#	ARTICLE	IF	CITATIONS
109	A novel approach to evaluate the immunogenicity of viral antigens of clinical importance in HLA transgenic murine models. <i>Immunology Letters</i> , 2008, 120, 108-116.	1.1	8
110	A fusion protein of HCMV IE1 exon4 and IE2 exon5 stimulates potent cellular immunity in an MVA vaccine vector. <i>Virology</i> , 2008, 377, 379-390.	1.1	27
111	Programmed Death-1 Expression in Liver Transplant Recipients as a Prognostic Indicator of Cytomegalovirus Disease. <i>Journal of Infectious Diseases</i> , 2008, 197, 25-33.	1.9	63
112	Impact of Donor Serostatus on CMV Reactivation and Reconstitution of Multi-Function CMV-Specific T Cells in CMV-Positive Transplant Recipients. <i>Blood</i> , 2008, 112, 4339-4339.	0.6	0
113	Longitudinal Assessment of Cytomegalovirus (CMV)-Specific Immune Responses in Liver Transplant Recipients at High Risk for Late CMV Disease. <i>Journal of Infectious Diseases</i> , 2007, 195, 633-644.	1.9	87
114	Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1. <i>Vaccine</i> , 2007, 25, 1132-1141.	1.7	30
115	Functional Characterization of BK Virus-Specific CD4 ⁺ T Cells with Cytotoxic Potential in Seropositive Adults. <i>Viral Immunology</i> , 2007, 20, 379-388.	0.6	73
116	An MVA vaccine overcomes tolerance to human p53 in mice and humans. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 1193-1205.	2.0	24
117	Oblimersen and \pm -interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium. <i>Journal of Cancer Research and Clinical Oncology</i> , 2007, 133, 705-711.	1.2	13
118	Pre-Clinical Development of a Subunit Vaccine Expressing an IE1-IE2 Fusion Protein of HCMV. <i>Blood</i> , 2007, 110, 165-165.	0.6	4
119	Multicytokine and Polyfunctional CMV-Specific T Cells Are Associated with Stem Cell Transplant Donor CMV Serostatus. <i>Blood</i> , 2007, 110, 4992-4992.	0.6	0
120	Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection. <i>Journal of Clinical Virology</i> , 2006, 35, 324-331.	1.6	36
121	Human cytomegalovirus vaccine: time to look for alternative options. <i>Trends in Molecular Medicine</i> , 2006, 12, 26-33.	3.5	71
122	Cross-reactive CTL recognizing two HLA-A*02-restricted epitopes within the BK virus and JC virus VP1 polypeptides are frequent in immunocompetent individuals. <i>Virology</i> , 2006, 350, 128-136.	1.1	30
123	In vitro expansion of polyclonal T-cell subsets for adoptive immunotherapy by recombinant modified vaccinia Ankara. <i>Experimental Hematology</i> , 2006, 34, 497-507.	0.2	22
124	Functional Comparison of T Cells Recognizing Cytomegalovirus pp65 and Intermediate-Early Antigen Polypeptides in Hematopoietic Stem Cell Transplant and Solid Organ Transplant Recipients. <i>Journal of Infectious Diseases</i> , 2006, 194, 1410-1421.	1.9	45
125	Vaccine Properties of a Novel Marker Gene-Free Recombinant Modified Vaccinia Ankara (MVA) Expressing Immunodominant CMV Antigens. <i>Blood</i> , 2006, 108, 2858-2858.	0.6	0
126	Functional Comparison and Longitudinal Assessment of Tri-Functional T-Cells Recognizing CMV pp65 and IE-1 Polypeptides in Hematopoietic Stem Cell and Solid Organ Transplant Recipients. <i>Blood</i> , 2006, 108, 2936-2936.	0.6	0

#	ARTICLE	IF	CITATIONS
127	Lack of association of cytomegalovirus with human brain tumors. <i>Modern Pathology</i> , 2005, 18, 838-843.	2.9	105
128	Reduced Type 1 and Type 2 Cytokines in Antiviral Memory T Helper Function Among Women Coinfected with HIV and HCV. <i>Journal of Clinical Immunology</i> , 2005, 25, 134-141.	2.0	12
129	Cross-Reactivity of T Lymphocytes Recognizing a Human Cytotoxic T-Lymphocyte Epitope within BK and JC Virus VP1 Polypeptides. <i>Journal of Virology</i> , 2005, 79, 11170-11178.	1.5	80
130	Simultaneous Reconstitution of Multiple Cytomegalovirus-Specific CD8+ Cell Populations with Divergent Functionality in Hematopoietic Stem Cell Transplant Recipients. <i>Journal of Infectious Diseases</i> , 2005, 191, 977-984.	1.9	28
131	Characterization of Host Immunity to cytomegalovirus pp150 (UL32). <i>Human Immunology</i> , 2005, 66, 116-126.	1.2	22
132	Cytomegalovirus Immune Reconstitution Occurs in Recipients of Allogeneic Hematopoietic Cell Transplants Irrespective of Detectable Cytomegalovirus Infection. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 890-902.	2.0	26
133	Novel conjugates of epitope fusion peptides with CpG-ODN display enhanced immunogenicity and HIV recognition. <i>Vaccine</i> , 2005, 23, 3453-3468.	1.7	37
134	Peptide Libraries to CMV Antigens Predict Levels of Cytotoxic Function of CMV-Specific CTL Populations in PBMC from HSCT Recipients.. <i>Blood</i> , 2005, 106, 478-478.	0.6	0
135	Development and Immunologic Characterization of Multi-Antigen Expressing Attenuated Poxviruses for Immunotherapy of CMV Infection in HSCT Recipients.. <i>Blood</i> , 2005, 106, 480-480.	0.6	0
136	CMV Immunity Status in Older (>50 Years Old) Subjects after Non-Myeloablative or Reduced Intensity Regimen for Hematopoietic Cell Transplantation (HCT): A Comparison with a Younger Cohort after Ablative HCT.. <i>Blood</i> , 2005, 106, 3246-3246.	0.6	0
137	Human Cytomegalovirus Proteins pp65 and Immediate Early Protein 1 Are Common Targets for CD8+ T Cell Responses in Children with Congenital or Postnatal Human Cytomegalovirus Infection. <i>Journal of Immunology</i> , 2004, 172, 2256-2264.	0.4	110
138	Two Distinct Pathways of Immuno-Modulation Improve Potency of p53 Immunization in Rejecting Established Tumors. <i>Cancer Research</i> , 2004, 64, 5407-5414.	0.4	48
139	Recombinant Modified Vaccinia Virus Ankara Expressing a Soluble Form of Glycoprotein B Causes Durable Immunity and Neutralizing Antibodies against Multiple Strains of Human Cytomegalovirus. <i>Journal of Virology</i> , 2004, 78, 3965-3976.	1.5	69
140	Assessment of cellular immunity to human cytomegalovirus in recipients of allogeneic stem cell transplants. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 433-447.	2.0	56
141	DNA and low titer, helper-free, recombinant AAV prime-boost vaccination for cytomegalovirus induces an immune response to CMV-pp65 and CMV-IE1 in transgenic HLA A*0201 mice. <i>Vaccine</i> , 2004, 23, 819-826.	1.7	16
142	Predominant type 1 CMV-Specific memory T-helper response in humans: evidence for gender differences in cytokine secretion. <i>Human Immunology</i> , 2004, 65, 476-485.	1.2	100
143	Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells. <i>Blood</i> , 2004, 104, 847-856.	0.6	42
144	Simultaneous Reconstitution of Multiple CMV-Specific CD8+ T-Cell Populations with Divergent Functionality in Hematopoietic Stem Cell Transplant Recipients.. <i>Blood</i> , 2004, 104, 190-190.	0.6	1

#	ARTICLE	IF	CITATIONS
145	Novel Conjugates of Epitope Fusion Peptides with CpG ODN Display Enhanced Immunogenicity and HIV Recognition.. Blood, 2004, 104, 3856-3856.	0.6	1
146	Rapid Ex Vivo Expansion of CMV Specific CTL Suitable for Clinical Immunotherapy Using CpG-DNA Matured PBMC Infected with Recombinant MVA.. Blood, 2004, 104, 5102-5102.	0.6	0
147	Relative dominance of HLA-B*07 restricted CD8+ T-Lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles. Human Immunology, 2003, 64, 440-452.	1.2	90
148	Relevance of Peptide Avidity to the T Cell Receptor for Cytomegalovirus-specific Ex Vivo CD8 T Cell Cytotoxicity. Journal of Infectious Diseases, 2003, 188, 908-918.	1.9	17
149	CTLA-4 Blockade Enhances the Therapeutic Effect of an Attenuated Poxvirus Vaccine Targeting p53 in an Established Murine Tumor Model. Journal of Immunology, 2003, 170, 3401-3407.	0.4	80
150	Immunization with Th-CTL Fusion Peptide and Cytosine-Phosphate-Guanine DNA in Transgenic HLA-A2 Mice Induces Recognition of HIV-Infected T Cells and Clears Vaccinia Virus Challenge. Journal of Immunology, 2003, 171, 4028-4039.	0.4	27
151	Characterization of cytotoxic function of CMV-pp65-specific CD8+ T-lymphocytes identified by HLA tetramers in recipients and donors of stem-cell transplants. Transplantation, 2002, 74, 722-732.	0.5	45
152	Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice. Blood, 2002, 100, 3681-3689.	0.6	67
153	A functional recombinant single-chain T cell receptor fragment capable of selectively targeting antigen-presenting cells. Cancer Immunology, Immunotherapy, 2002, 51, 565-573.	2.0	8
154	Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses. Immunology, 2002, 106, 113-121.	2.0	61
155	Kinase-Deficient CMVpp65 Triggers a CMVpp65 Specific T-Cell Immune Response in HLA-A*0201.Kb Transgenic Mice after DNA Immunization. Scandinavian Journal of Immunology, 2002, 55, 592-598.	1.3	10
156	Site-directed mutation in a conserved kinase domain of human cytomegalovirus-pp65 with preservation of cytotoxic T lymphocyte targeting. Vaccine, 2001, 19, 1628-1635.	1.7	25
157	Enhanced immune activity of cytotoxic T-lymphocyte epitope analogs derived from positional scanning synthetic combinatorial libraries. Blood, 2001, 97, 1776-1786.	0.6	68
158	Population coverage by HLA class-I restricted cytotoxic T-lymphocyte epitopes. Immunogenetics, 2001, 52, 165-173.	1.2	107
159	Human Immunodeficiency Virus-infected Patients Receiving Highly Active Antiretroviral Therapy Maintain Activated CD8+T Cell Subsets as a Strong Adaptive Immune Response to Cytomegalovirus. Journal of Infectious Diseases, 2001, 184, 256-267.	1.9	25
160	Infrequent Occurrence of Natural Mutations in the pp65 495-503 Epitope Sequence Presented by the HLA A*0201 Allele among Human Cytomegalovirus Isolates. Journal of Virology, 2001, 75, 2472-2474.	1.5	23
161	Status of Cytomegalovirus Prevention and Treatment in 2000. Hematology American Society of Hematology Education Program, 2000, 2000, 339-355.	0.9	37
162	Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice: dependence on HLA class II restricted TH response. Human Immunology, 2000, 61, 764-779.	1.2	74

#	ARTICLE	IF	CITATIONS
163	Status of Cytomegalovirus Prevention and Treatment in 2000. Hematology American Society of Hematology Education Program, 2000, 2000, 339-355.	0.9	4
164	Status of Cytomegalovirus Prevention and Treatment in 2000. Hematology American Society of Hematology Education Program, 2000, 2000, 339-355.	0.9	3
165	Targeting of human p53-overexpressing tumor cells by an HLA A*0201-restricted murine T-cell receptor expressed in Jurkat T cells. Cancer Research, 2000, 60, 693-701.	0.4	20
166	An orthotopic in vivo model of human pancreatic cancer. Surgery, 1999, 126, 562-567.	1.0	48
167	IMMUNOTHERAPY OF BLADDER CANCER TARGETING P53. Journal of Urology, 1999, 162, 1806-1811.	0.2	11
168	IMMUNOTHERAPY OF BLADDER CANCER TARGETING P53. Journal of Urology, 1999, , 1806.	0.2	2
169	An HLA-restricted, p53 specific immune response from HLA transgenic p53 knockout mice. Annals of Surgical Oncology, 1998, 5, 93-99.	0.7	10
170	Targeting p53 for adoptive T-cell immunotherapy. Cancer Research, 1998, 58, 2601-5.	0.4	22
171	The Use of Transgenic Mice to Generate High Affinity p53 Specific Cytolytic T Cells. Journal of Surgical Research, 1997, 69, 337-343.	0.8	28
172	Development of a Candidate HLA A*0201 Restricted Peptide-Based Vaccine Against Human Cytomegalovirus Infection. Blood, 1997, 90, 1751-1767.	0.6	237
173	Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood, 1997, 90, 1751-67.	0.6	68
174	IMMUNOHISTOCHEMICAL ANALYSIS OF T CELL PHENOTYPES IN PATIENTS WITH GRAFT-VERSUS-HOST DISEASE FOLLOWING ALLOGENEIC BONE MARROW TRANSPLANTATION. Transplantation, 1995, 59, 1436-1444.	0.5	28
175	Immunochemical and molecular analysis of antigen binding to lipid anchored and soluble forms of an mhc independent human $\hat{I}\hat{I}^2$ T cell receptor. Molecular Immunology, 1994, 31, 857-872.	1.0	1
176	Inhibition or activation of human T cell receptor transfectants is controlled by defined, soluble antigen arrays.. Journal of Experimental Medicine, 1992, 176, 1421-1430.	4.2	42
177	Characterization of nuclear protein binding to the interferon- \hat{I}^3 promoter in quiescent and activated human T cells. European Journal of Immunology, 1992, 22, 2419-2428.	1.6	28
178	The human interferon- \hat{I}^3 gene contains an inducible promoter that can be transactivated by tax I and II. European Journal of Immunology, 1991, 21, 1879-1885.	1.6	54
179	Major histocompatibility complex independent T cell receptor-antigen interaction: functional analysis using fluorescein derivatives.. Journal of Experimental Medicine, 1991, 174, 229-241.	4.2	20
180	Lineage-specific expression of a T cell receptor variable gene promoter controlled by upstream sequences.. Journal of Experimental Medicine, 1989, 169, 1213-1231.	4.2	23

#	ARTICLE	IF	CITATIONS
181	Exon-intron organization and sequence comparison of human and murine T11 (CD2) genes.. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 1615-1619.	3.3	33
182	The gene for T11 (CD2) maps to chromosome 1 in humans and to chromosome 3 in mice. Journal of Immunology, 1988, 140, 3617-21.	0.4	10
183	Unusual organization and diversity of T-cell receptor a-chain genes. Nature, 1985, 316, 828-832.	13.7	221
184	Effects of Rat Growth Hormone (rGH)-Releasing Factor and Somatostatin on the Release and Synthesis of rGH in Dispersed Pituitary Cells*. Endocrinology, 1985, 117, 457-467.	1.4	88
185	Regulation of growth hormone messenger RNA synthesis by dexamethasone and triiodothyronine. Journal of Molecular Biology, 1985, 181, 41-62.	2.0	171
186	Disproportionate expression of the two nonallelic rat insulin genes in a pancreatic tumor is due to translational control. Cell, 1982, 31, 531-542.	13.5	83